Literature DB >> 20440531

Comparative study for the virulence of Mycobacterium avium isolates from patients with nodular-bronchiectasis- and cavitary-type diseases.

Y Tatano1, K Yasumoto, T Shimizu, C Sano, K Sato, S Yano, H Takeyama, H Tomioka.   

Abstract

Mycobacterium avium (Mav) lung infections, called nodular-bronchiectasis (NB)-type M. avium complex (MAC) disease, are globally increasing. To elucidate whether there are unusual populations of Mav, causing NB-type disease rather than cavitary (CA)-type disease, we compared the virulence of Mav isolates from patients with NB-type (NB-Mav) and those from CA-type (CA-Mav) diseases, based on intracellular growth in various types of human cells. Five strains each of NB-Mav and CA-Mav were compared with each other for their invasiveness and ability to intracellularly replicate in various types of cultured cells of human origin. The two types of Mav isolates showed a similar ability, on average, to replicate in macrophages and lung epithelial cells. Moreover, they showed a similar ability to induce the production of reactive nitrogen intermediates and reactive oxygen intermediates by macrophages and susceptibility to antimicrobial molecules. Therefore, it appears that there is no essential difference in virulence in terms of infectivity to human macrophages and lung cells between Mav strains isolated from NB-MAC disease and those from CA-MAC disease. These findings indicate the importance of further studies to elucidate the mechanism for the establishment of NB-type MAC diseases based on host immunological conditions rather than the pathogenic nature of MAC organisms themselves.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20440531     DOI: 10.1007/s10096-010-0930-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  18 in total

1.  Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells.

Authors:  Haruaki Tomioka; Katsumasa Sato; Chiaki Sano; Keisuke Sano; Toshiaki Shimizu
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Comparative roles of free fatty acids with reactive nitrogen intermediates and reactive oxygen intermediates in expression of the anti-microbial activity of macrophages against Mycobacterium tuberculosis.

Authors:  T Akaki; H Tomioka; T Shimizu; S Dekio; K Sato
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

3.  Combined effects of ATP on the therapeutic efficacy of antimicrobial drug regimens against Mycobacterium avium complex infection in mice and roles of cytosolic phospholipase A2-dependent mechanisms in the ATP-mediated potentiation of antimycobacterial host resistance.

Authors:  Haruaki Tomioka; Chiaki Sano; Katsumasa Sato; Keiko Ogasawara; Tatsuya Akaki; Keisuke Sano; Shan Shan Cai; Toshiaki Shimizu
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

4.  Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome.

Authors:  J M Reich; R E Johnson
Journal:  Chest       Date:  1992-06       Impact factor: 9.410

5.  Mycobacterium avium in a shower linked to pulmonary disease.

Authors:  Joseph O Falkinham; Michael D Iseman; Petra de Haas; Dick van Soolingen
Journal:  J Water Health       Date:  2008-06       Impact factor: 1.744

6.  Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis.

Authors:  Richard J Wallace; Yansheng Zhang; Barbara A Brown-Elliott; Mitchell A Yakrus; Rebecca W Wilson; Linda Mann; Leslie Couch; William M Girard; David E Griffith
Journal:  J Infect Dis       Date:  2002-06-25       Impact factor: 5.226

7.  Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome.

Authors:  Richard D Kim; David E Greenberg; Mary E Ehrmantraut; Shireen V Guide; Li Ding; Yvonne Shea; Margaret R Brown; Milica Chernick; Wendy K Steagall; Connie G Glasgow; JingPing Lin; Clara Jolley; Lynn Sorbara; Mark Raffeld; Suvimol Hill; Nilo Avila; Vandana Sachdev; Lisa A Barnhart; Victoria L Anderson; Reginald Claypool; Dianne M Hilligoss; Mary Garofalo; Alan Fitzgerald; Sandra Anaya-O'Brien; Dirk Darnell; Rosamma DeCastro; Heather M Menning; Stacy M Ricklefs; Stephen F Porcella; Kenneth N Olivier; Joel Moss; Steven M Holland
Journal:  Am J Respir Crit Care Med       Date:  2008-08-14       Impact factor: 21.405

8.  CFTR gene mutations in Japanese individuals with congenital bilateral absence of the vas deferens.

Authors:  Chieko Anzai; Nasa Morokawa; Hiroshi Okada; Sadao Kamidono; Yoshikatsu Eto; Kunihiko Yoshimura
Journal:  J Cyst Fibros       Date:  2003-03       Impact factor: 5.482

9.  Infection with Mycobacterium avium complex in patients without predisposing conditions.

Authors:  D S Prince; D D Peterson; R M Steiner; J E Gottlieb; R Scott; H L Israel; W G Figueroa; J E Fish
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

10.  Polyclonal Mycobacterium avium complex infections in patients with nodular bronchiectasis.

Authors:  R J Wallace; Y Zhang; B A Brown; D Dawson; D T Murphy; R Wilson; D E Griffith
Journal:  Am J Respir Crit Care Med       Date:  1998-10       Impact factor: 21.405

View more
  4 in total

1.  Clinical characteristics and prognosis of nontuberculous mycobacterial lung disease with different radiographic patterns.

Authors:  Chin-Chung Shu; Chih-Hsin Lee; Chia-Lin Hsu; Jann-Tay Wang; Jann-Yuan Wang; Chong-Jen Yu; Li-Na Lee
Journal:  Lung       Date:  2011-09-29       Impact factor: 2.584

2.  Correlation between variable-number tandem-repeat-based genotypes and drug susceptibility in Mycobacterium avium isolates.

Authors:  Y Tatano; C Sano; K Yasumoto; T Shimizu; K Sato; K Nishimori; T Matsumoto; S Yano; H Takeyama; H Tomioka
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-12       Impact factor: 3.267

Review 3.  Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights.

Authors:  Pamela J McShane; Jeffrey Glassroth
Journal:  Chest       Date:  2015-12       Impact factor: 9.410

4.  Nontuberculous Mycobacteria Show Differential Infectivity and Use Phospholipids to Antagonize LL-37.

Authors:  Jennifer R Honda; Tamara Hess; Rachel Carlson; Pitchaimani Kandasamy; Luisa Maria Nieto Ramirez; Grant J Norton; Ravleen Virdi; M Nurul Islam; Carolina Mehaffy; Nabeeh A Hasan; L Elaine Epperson; Danny Hesser; Scott Alper; Michael Strong; Sonia C Flores; Dennis R Voelker; Karen M Dobos; Edward D Chan
Journal:  Am J Respir Cell Mol Biol       Date:  2020-03       Impact factor: 6.914

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.